Significance of thrombocytopenia in myelodysplastic syndromes: Associations and prognostic implications

Clinical Lymphoma, Myeloma and Leukemia

Volumn 11, Issue 2, 2011, Pages 237-241

  Al Ameri, Ali ^a   Jabbour, Elias ^a   Garcia Manero, Guillermo ^a   O'Brien, Susan ^a   Faderl, Stefan ^a   Ravandi, Farhad ^a   Shan, Jianqin ^a   Pierce, Sherry ^a   Cortes, Jorge ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Myelodysplastic syndrome; outcome; Thrombocytopenia

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLEEDING; CAUSE OF DEATH; CYTOPENIA; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FUNCTIONAL STATUS; GASTROINTESTINAL HEMORRHAGE; HUMAN; INCIDENCE; INFECTION; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KARYOTYPE; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; MYELODYSPLASTIC SYNDROME; PROGNOSIS; SURVIVAL RATE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; ADOLESCENT; MIDDLE AGED; MORTALITY; SURVIVAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PLATELET COUNT; PROGNOSIS; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; YOUNG ADULT;

EID: 80052822000     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2011.03.005     Document Type: Article

References (13)

1. J.M. Bennett, R.D. Brunning, and J.W. Vardiman Myelodysplastic syndromes: from French-American-British to World Health Organization: a commentary Blood 99 2002 3074 3075 (Pubitemid 34525407)
2. J.W. Vardiman, J. Thiele, and D.A. Arber The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes Blood 114 2009 937 951
3. P. Greenberg, C. Cox, and M.M. LeBeau International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 1997 2079 2088 (Pubitemid 27132124)
4. H. Kantarjian, S. O'Brien, and F. Ravandi Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System Cancer 113 2008 1351 1361
5. B.D. Cheson, J.M. Bennett, and H. Kantarjian Report of an international working group to standardize response criteria for myelodysplastic syndromes Blood 96 2000 3671 3674
6. J. Neukirchen, S. Blum, and A. Kuendgen Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes Eur J Haematol 83 2009 477 482
7. H. Kantarjian, F. Giles, and A. List The incidence and impact of thrombocytopenia in myelodysplastic syndromes Cancer 109 2007 1705 1714 (Pubitemid 46668530)
8. U. Germing, U. Platzbecker, A. Giagounidis, and C. Aul Platelet morphology, platelet mass, platelet count and prognosis in patients with myelodysplastic syndromes Br J Haematol 138 2007 399 400 (Pubitemid 47035388)
9. K.M. Bowles, B.A. Warner, and T.P. Baglin Platelet mass has prognostic value in patients with myelodysplastic syndromes Br J Haematol 135 2006 198 200 (Pubitemid 44401616)
10. D.R. Cox The Analysis of Binary Data 1970 Methuen London
11. F. Dayyani, A.P. Conley, and S.S. Strom Cause of death in patients with lower-risk myelodysplastic syndrome Cancer 116 2010 2174 2179
12. H. Kantarjian, P. Fenaux, and M.A. Sekeres Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia J Clin Oncol 28 2010 437 444
13. H. Kantarjian, F. Giles, and P. Greenberg Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine ASH Annual Meeting Abstracts 112 11 2008 224